4D Molecular Therapeutics Inc (FDMT) Stock Price, Quote & News

Company Profile

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degene...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 505 2680

Website: www.4dmoleculartherapeutics.com

Address:

5858 Horton Street, Suite 455, EmeryVille, United States

eeyore1 Feb. 23 at 4:51 AM

$FDMT 20.42% short float — that’s serious fuel. It won’t take much upside momentum to start forcing covers. If this catches a bid, the squeeze could be sharp and fast.

0 · Reply

vulture2 Feb. 23 at 4:48 AM

$FDMT The real catalyst clock is ticking toward H1 2027 with 4FRONT-1 Phase 3 topline for 4D-150. That’s the kind of event that can completely re-rate a biotech. Between now and then, every update tightens the setup. Patience into a registrational readout — that’s where the asymmetric upside lives.

0 · Reply

UgoGreg Feb. 21 at 3:50 PM

$FDMT https://youtu.be/ygBN8MilTyc

0 · Reply

xxxxxxx01 Feb. 20 at 6:57 PM

$FDMT $IBRX 2 biotechs that will carry my portfolio for the next 2 years 🔥🔥🔥🔥unbelievable companies

0 · Reply

ReturnOfEsquire Feb. 19 at 4:12 PM

$FDMT Let's go baby...

0 · Reply

Larrymme Feb. 19 at 2:57 PM

$FDMT

0 · Reply

vulture2 Feb. 19 at 3:26 AM

$FDMT 4.3 “rescue shots over 24 months” isn’t “about the same as Eylea” — that’s supplemental anti-VEGF after a one-time 4D-150 dose (and it’s from the toughest PRISM cohort). PRISM breaks it out by 6-month chunks (~0.5 / 1.3 / 1.2 / 1.2 = ~4.2 total through 24 mo). The Phase 3 comparator is projected aflibercept q8w (i.e., way more injections). Apples vs oranges.

1 · Reply

Aawilliam2003 Feb. 18 at 5:16 PM

$FDMT can someone help with the hype here. Doesn’t their data show 4.3 rescue shots over 24 months? Isn’t that about the same as Elena?

2 · Reply

xxxxxxx01 Feb. 17 at 8:30 PM

$OCUL very happy with my position on this . This will be best in class until $FDMT takes over I Will hold until buyout or until they file a NDA

0 · Reply

ReturnOfEsquire Feb. 17 at 4:38 PM

$FDMT This is where OCUL failed. Durability is far worse than our 92% injection free in treatment naive.

1 · Reply

4DMT to Participate in Upcoming Investor Conferences

Feb 13, 2026, 4:05 PM EST - 10 days ago

4DMT Announces New Employment Inducement Grants

Feb 9, 2026, 8:00 AM EST - 14 days ago

4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD

Jan 14, 2026, 1:35 PM EST - 5 weeks ago

4D Molecular Therapeutics, Inc. (FDMT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 7, 2026, 8:00 AM EST - 6 weeks ago

4DMT Provides Company Update and Anticipated Development Milestones for 2026

Dec 17, 2025, 12:59 PM EST - 2 months ago

4D Molecular Therapeutics, Inc. (FDMT) Discusses Interim Phase I Data From AEROW Trial in Cystic Fibrosis and Platform Potential Transcript

Dec 17, 2025, 7:00 AM EST - 2 months ago

4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease

Dec 8, 2025, 8:00 AM EST - 2 months ago

4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference

Nov 21, 2025, 7:43 PM EST - 3 months ago

4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 20, 2025, 8:00 AM EST - 3 months ago

4DMT to Participate in 8th Annual Evercore Healthcare Conference

Nov 17, 2025, 6:00 AM EST - 3 months ago

4DMT Appoints Kristian Humer as Chief Financial Officer

Nov 10, 2025, 8:00 AM EST - 3 months ago

4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

Nov 6, 2025, 4:05 PM EST - 3 months ago

4DMT to Participate in Jefferies 2025 London Healthcare Conference

Nov 6, 2025, 6:23 AM EST - 3 months ago

4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants

Nov 6, 2025, 6:00 AM EST - 3 months ago

4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150's Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years

Oct 30, 2025, 11:02 PM EDT - 4 months ago

4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific

Oct 14, 2025, 8:00 AM EDT - 4 months ago

4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference

Oct 13, 2025, 8:00 AM EDT - 4 months ago

4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation

Sep 30, 2025, 5:08 AM EDT - 5 months ago

4D Molecular Therapeutics: This Gene Therapy Company May Soon Surprise Investors

Sep 9, 2025, 6:13 PM EDT - 5 months ago

4D Molecular Therapeutics, Inc. (FDMT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 2, 2025, 8:00 AM EDT - 6 months ago

4DMT Announces Leadership Expansion with Proven Late-Stage Executives to Drive 4D-150 Execution and BLA Readiness

Aug 11, 2025, 8:00 AM EDT - 7 months ago

4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

Aug 6, 2025, 8:00 AM EDT - 7 months ago

4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 1, 2025, 10:29 AM EDT - 7 months ago

4D Molecular Therapeutics Rallies On Heels Of Diabetes-Related Vision Study

Jul 31, 2025, 4:05 PM EDT - 7 months ago

4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update

Jul 24, 2025, 8:00 AM EDT - 7 months ago

4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists

Jul 2, 2025, 4:05 PM EDT - 8 months ago

4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution

May 8, 2025, 4:05 PM EDT - 10 months ago

4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

May 1, 2025, 8:00 AM EDT - 10 months ago

4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME

Mar 10, 2025, 8:00 AM EDT - 1 year ago

4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD

Feb 28, 2025, 4:05 PM EST - 1 year ago

4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

Feb 18, 2025, 2:33 PM EST - 1 year ago

4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression

Feb 10, 2025, 10:26 AM EST - 1 year ago

Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study

Feb 8, 2025, 2:30 PM EST - 1 year ago

4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program

Nov 13, 2024, 4:05 PM EST - 1 year ago

4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

Nov 4, 2024, 11:00 AM EST - 1 year ago

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Encourages Investor Participation

Nov 2, 2024, 11:00 AM EDT - 1 year ago

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Reach Out

Oct 30, 2024, 11:00 AM EDT - 1 year ago

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Impacted Investors To Reach Out

Oct 28, 2024, 11:00 AM EDT - 1 year ago

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Take Part

Oct 18, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Encourages Investors To Help Investigate 4D Molecular Therapeutics Inc For Possible Securities Fraud

Oct 16, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Urges Investor Participation In An Investigation Into 4D Molecular Therapeutics Inc For Securities Fraud

Oct 14, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Urges Investors To Help Investigate Whether 4D Molecular Therapeutics Inc Committed Securities Fraud

eeyore1 Feb. 23 at 4:51 AM

$FDMT 20.42% short float — that’s serious fuel. It won’t take much upside momentum to start forcing covers. If this catches a bid, the squeeze could be sharp and fast.

0 · Reply

vulture2 Feb. 23 at 4:48 AM

0 · Reply

UgoGreg Feb. 21 at 3:50 PM

$FDMT https://youtu.be/ygBN8MilTyc

0 · Reply

xxxxxxx01 Feb. 20 at 6:57 PM

$FDMT $IBRX 2 biotechs that will carry my portfolio for the next 2 years 🔥🔥🔥🔥unbelievable companies

0 · Reply

ReturnOfEsquire Feb. 19 at 4:12 PM

$FDMT Let's go baby...

0 · Reply

Larrymme Feb. 19 at 2:57 PM

$FDMT

0 · Reply

vulture2 Feb. 19 at 3:26 AM

1 · Reply

Aawilliam2003 Feb. 18 at 5:16 PM

$FDMT can someone help with the hype here. Doesn’t their data show 4.3 rescue shots over 24 months? Isn’t that about the same as Elena?

2 · Reply

xxxxxxx01 Feb. 17 at 8:30 PM

$OCUL very happy with my position on this . This will be best in class until $FDMT takes over I Will hold until buyout or until they file a NDA

0 · Reply

ReturnOfEsquire Feb. 17 at 4:38 PM

$FDMT This is where OCUL failed. Durability is far worse than our 92% injection free in treatment naive.

1 · Reply

ReturnOfEsquire Feb. 17 at 4:20 PM

$FDMT EYPT up 20% and we're almost flat with no new watchers. I like the setup for a drop at some point.

0 · Reply

ReturnOfEsquire Feb. 17 at 4:13 PM

$FDMT As I expected, OCUL is no threat if injection-free is 69%. We are still best in class all things considered. Now we just need some orchestrated drop to get some cheaper shares.

0 · Reply

xxxxxxx01 Feb. 17 at 12:36 PM

$OCUL $FDMT will be far superior to ocul when it comes out …. So ocul can enjoy their market share until 4d150 is approved. Still decent results none the less il be buying if it stays lower.

0 · Reply

senior_nurse Feb. 15 at 3:22 AM

$FDMT You can do nothing, buy more, sell covered calls, trim partially, or sell everything. Why do you want someone else to make the decision for you? Be the man — make the call yourself. It builds character.

0 · Reply

McMillion1 Feb. 15 at 1:28 AM

$FDMT I’m up 95%. What should I do?

1 · Reply

ReturnOfEsquire Feb. 14 at 3:29 AM

$FDMT https://finance.yahoo.com/news/ocular-therapeutix-announce-topline-data-220000262.html

0 · Reply

Larrymme Feb. 13 at 10:31 PM

$FDMT ocular data set to release tues am...lets hope it's good and then that this one cooperates and gets it act together so we can load andload some more

0 · Reply

senior_nurse Feb. 13 at 8:32 PM

$FDMT 40 April 17 $7.5 calls at $2.50. Small size, but directional. That’s a bet on double digits by April. Momentum building.

0 · Reply

ReturnOfEsquire Feb. 13 at 4:44 PM

$FDMT 10$ is a magic number for many institutions and platforms. That’s the number to watch. This action is just noise. They can rip it down at any time.

0 · Reply

ReturnOfEsquire Feb. 11 at 4:52 PM

$FDMT Looks like 9 is the new 11. Would love to see a big dip soon. I'm waiting...

2 · Reply

VivianRockmore733 Feb. 11 at 4:23 PM

$FDMT 4D Molecular Therapeutics; gene therapy biotech; early-stage; platform technology; clinical catalysts.

0 · Reply

xxxxxxx01 Feb. 9 at 6:34 PM

$FDMT High tute owner ship saving this dog from the shorts. This board is like a ghost town.

0 · Reply

Market Cap	515.36M
Revenue (ttm)	40,000.00
Net Income (ttm)	-160.87M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-402,175.00%
Debt to Equity Ratio	0.00

Volume	666,391
Avg Vol	926,882
Day's Range	N/A - N/A
Shares Out	57.14M
Stochastic %K	32%
Beta	3.01
Analysts	Strong Sell
Price Target	$33.11